18 May 2015
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative epilepsy and other neuropsychiatric therapeutics, announced that Gail M. Farfel, Ph.D., Chief Clinical and Regulatory Officer of Marinus, presented clinical data on ganaxolone in drug-resistant pediatric epilepsies at the Antiepileptic Drug and Device Trials (AED) XIII conference on Friday, May 15, 2015.
Big Pharma's a C student, rep study finds, with Bayer at the top, Novartis at bottom
18 May 2015
When it comes to Big Pharma's reputation, "average" says it all. That's the story from the research firm Reputation Institute, which perennially puts major drugmakers right smack in the middle of its scorecard. In other words, pharma is a C student.
New glaucoma devices bring new dimension of treatment
18 May 2015
The loss of visual acuity associated with glaucoma may be an indirect result of increased IOP. But increased IOP is rarely the result of excessive aqueous production. It is usually an insufficiency in aqueous outflow.
Surge in overseas investment drives Israel to life sci fundraising record
18 May 2015
Israel has joined the list of countries that obliterated their life science fundraising records in 2014. Data from IVC Research Center show Israeli life science companies pulled in $801 million (€708 million) last year, a 55% jump on the previous high that was underpinned by foreign investors opening their checkbooks with unprecedented regularity.
Which global markets should drugmakers target? China, yes--but old European standbys, too
18 May 2015
Big Pharma has some serious ground to cover when it comes to global sales and marketing. Worldwide spending for prescription branded drugs and generic medicines is set to increase 30% from 2013-2018 with $1.3 trillion in annual global drug sales on the line, according to data from the Institute of Healthcare Informatics cited by The Motley Fool blog. And drugmakers should look at markets around the world for their cut of the revenues.
Japan readies to sign new IP law it sees as win-win
18 May 2015
Japan is due to sign off on an international intellectual property patent treaty that would require it to make some reforms in its own laws to make it easier for foreigners to apply. But its own exporting companies also stand to benefit.
The 25 most influential people in biopharma in 2015
15 May 2015
A lot of people make news in the biopharma business. Few of them are influential. Influence, simply put, is the ability to make your mark in such a way as to get other prominent people in this business to rethink the way they do business.
FDA Revises Field Inspections to Reflect Global Market and Quality Initiatives
15 May 2015
The globalization of drug production has prompted FDA to overhaul its strategies for ensuring the safety and quality of drugs and biologics coming into the United States, as well as those produced at home. Recent legislation enhancing FDA inspection authority supports stiffer enforcement of manufacturing standards, along with added incentives for establishing high quality operations.
Next opportunity: Will China's e-commerce revolution lead to accessible biologics?
15 May 2015
Each year investors looking to ride the next big wave of opportunity convene at China's Healthcare Investment Conference to test the waters. This year, the promise of technology to tackle some of China's most complicated health care woes, summed up by the term e-Health, generated the most buzz.
As IPO market wanes, biotechs turn to reverse mergers
15 May 2015
Through the first four months of the year, BioWorld Snapshots tracked 24 IPOs by drug companies on U.S. and international exchanges compared to 36 in the same time period last year.
06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
87% of cancer patients give positive ratings for medical care quality
18 September 2024
The Russian market of fillers and biorevitalizers grew by 21% in the first half of 2024
18 September 2024
Pharma’s Patient Reach Problem: Billions Still Left Behind
17 September 2024
17 September 2024